Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.61 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31635268 | 0.88 | HDAC1 (0.78) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL11396983 | 0.88 | HDAC1 (0.78) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL8927259 | 0.84 | KMT2A (0.84) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL15480414 | 0.82 | HDAC1 (0.69) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL8363038 | 0.81 | HDAC1 (0.72) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL15480408 | 0.81 | HDAC3 (1.00) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL8271097 | 0.80 | MEN1 (0.70) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL10411598 | 0.80 | KMT2A (0.70) | MEN1KMT2AHDAC1HDAC2HDAC6 | |
| SCHEMBL8556893 | 0.80 | KMT2A (0.77) | MEN1KMT2AHDAC1HTT | |
| SCHEMBL12819302 | 0.79 | KMT2A (0.76) | MEN1KMT2AHDAC1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | MEN1 4342/4885KMT2A 223/4885HDAC1 2/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | MEN1 4342/4885KMT2A 223/4885HDAC1 2/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | MEN1 4342/4885KMT2A 223/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.